$ZOMDF · Zomedica Corp.
Zomedica filed an 8-K (Item 2.02) announcing Q3 FY2026 results for the quarter ended September 30, 2026. Revenue rose 22% YoY to a record $9.9M, the second straight quarter above $9M, with 23 consecutive quarters of YoY growth. Net loss narrowed 48% to $3.2M from $6.1M, and cash burn improved 32% to $3.2M, the lowest third-quarter burn on record. Liquidity stood at $40.9M as of September 30, 2026.
- Q3 revenue hit a record $9.9M, up 22% YoY from $8.1M.
- Diagnostic revenue jumped 113% YoY to $1.6M for the quarter.
- Net loss narrowed 48% to $3.2M from $6.1M a year earlier.
- Cash burn improved 32% to $3.2M, the lowest Q3 burn on record.
- Liquidity totaled $40.9M as of September 30, 2026.
Price data unavailable.
A small-cap animal-health firm showing accelerating revenue growth and sharply narrowing losses while holding $40.9M in liquidity.
Animal-health point-of-care diagnostics and therapeutics; growth driven by PulseVet/Assisi devices and a Boehringer Ingelheim collaboration.
Development Services revenue may not continue; 2025 results included a $55.8M non-cash impairment tied to market-cap decline, with no such charge in 2026.